We observed a positive correlation between EDSS and both baseline and follow-up serum CCL11, although no significant differences were found in serum and CSF levels in our cohort, likely due to the lack of progressive MS cases and healthy controls. The gene discussed is CCL11; the disease is myeloid sarcoma.